SciELO - Scientific Electronic Library Online

vol.10 número2Identificación de potenciales biomarcadores de calcificación vascular en pacientes con diabetes mellitus tipo 2 mediante el uso de herramientas bioinformáticas de libre accesoCalcifediol mensual frente a calcifediol quincenal en el tratamiento de pacientes osteoporóticos. Estudio en la vida real índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google


Revista de Osteoporosis y Metabolismo Mineral

versión On-line ISSN 2173-2345versión impresa ISSN 1889-836X


PINEDA-MONCUSI, M et al. Study of the genetic basis of Trabecular Bone Score reduction related to aromatase inhibitors. Rev Osteoporos Metab Miner [online]. 2018, vol.10, n.2, pp.82-88.  Epub 17-Mayo-2021. ISSN 2173-2345.


Aromatase inhibitors (AI) are effective adjuvant endocrine therapies for breast cancer patients, although they have been associated with an increased risk of osteoporotic fracture. Trabecular Bone Score (TBS) loss has been previously demonstrated, although it may vary among AI-treated patients. This study aims to identify the genetic basis associated with TBS change by studying steroidogenic pathway genes.

Material and methods:

The B-ABLE cohort studies prospectively postmenopausal women with breast cancer under treatment with AI. TBS is calculated from the raw data acquired in dual-energy x-ray absorptiometry (DXA) scan at the outset of the study and at the end of AI-treatment. The relative TBS change was calculated as the percentage variation of the TBS value at the end of treatment from baseline. To study the possible genetic association, nucleotide polymorphisms (SNPs) were genotyped in genes CYP11A1, CYP17A1, HDE3B2, HDE17B3, CYP19A1, CYP2C19, CYP2C9, ESR1, GC, CYP27B1, VDR and CYP24A1. The possible relationship between genes and TBS changes was studied by multiple linear regression, considering models of dominant, recessive and additive genetic inheritance.


The study included 212 women that had not been treated with bisphosphonates and had available TBS data. Half of the patients had been treated previously with tamoxifen. The percentage of intraindividual TBS change was -0.04% [95% CI: -0.05 to -0.03; p<0.001] at the end of AI treatment. The SNP rs6013897 in the gene CYP24A1 showed a significant association with TBS reduction [p=0.03565; coefficient β (95% CI) = -1.55 (-2.98 to -0.11)].


The CYP24A1 gene could be involved in the phenotypic variability found in bone microarchitecture deterioration during AI treatment.

Palabras clave : aromatase inhibitors; breast cancer; TBS; genetic association study.

        · resumen en Español     · texto en Español | Inglés     · Español ( pdf ) | Inglés ( pdf )